AgingResearch.NewsJoin free

Butyrolactone ii

Intervention

1 paper4 findings

PubChem 10405953

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Innovative Research Group Project of the National Natural Science Foundation of China and 1 more
  • Model organisms1

Outcomes

3

Lifespan

upin worms1+20% to +26%

1 study

  1. Butyrolactone ii extends lifespan in worms (+26%).

    “significantly increased median lifespan and maximum lifespan by 20% and 26% respectively”

    Model organismsin CL2355 nematodes

    Neuroprotective effects of butyrolactone II from Aspergillus terreus via Nrf-2/SKN-1 pathway modulation in Caenorhabditis elegans

    The Journal of nutritional biochemistry9 Sep 2025

  2. Butyrolactone ii extends lifespan in worms (+20%).

    “significantly increased median lifespan and maximum lifespan by 20% and 26% respectively”

    Model organismsin CL2355 nematodes

    Neuroprotective effects of butyrolactone II from Aspergillus terreus via Nrf-2/SKN-1 pathway modulation in Caenorhabditis elegans

    The Journal of nutritional biochemistry9 Sep 2025

Paralysis rate

downin worms1−9.8%

1 study

  1. Butyrolactone ii decreases paralysis rate in worms (-9.8%).

    “reduced the sensitivity of nematodes to 5-HT, decreasing the paralysis rate by 9.8% (P<0.05)”

    Model organismsin CL2355 nematodes

    Neuroprotective effects of butyrolactone II from Aspergillus terreus via Nrf-2/SKN-1 pathway modulation in Caenorhabditis elegans

    The Journal of nutritional biochemistry9 Sep 2025

Chemotaxis index

upin worms1+15%

1 study

  1. Butyrolactone ii improves chemotaxis index in worms (+15.06%).

    “treatment significantly elevated the chemotaxis index of genotyped nematode CL2355 by 15.06% (P<0.05)”

    Model organismsin CL2355 nematodes

    Neuroprotective effects of butyrolactone II from Aspergillus terreus via Nrf-2/SKN-1 pathway modulation in Caenorhabditis elegans

    The Journal of nutritional biochemistry9 Sep 2025

Latest

Related